Sharmila Makhija named chair of the Department of Obstetrics & Gynecology and Women’s Health at Albert Einstein College of Medicine

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

SHARMILA MAKHIJA was named professor and chair of the Department of Obstetrics & Gynecology and Women’s Health at Albert Einstein College of Medicine and Montefiore Health System, effective April 1.

Previously, Makhija served as chair and professor of obstetrics and gynecology at University of Louisville School Of Medicine.

Makhija has also held faculty positions at the University of Pittsburgh School of Medicine/Magee-Women’s Hospital, the University of Alabama at Birmingham School of Medicine, and Emory University School of Medicine.

She is a fellow of the American College of Obstetrics and Gynecology and a member of the American Medical Association, American Association of Cancer Research, and the American Society of Gynecologic Cancer. She is on the editorial board of the Journal of Oncology Practice and has served on the editorial boards of Women’s Oncology Review Journal and the International Journal of Gynecological Cancer.

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login